Engineered immune cells take on deadly brain tumor

NCT ID NCT07244666

Not yet recruiting Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new type of immunotherapy for recurrent glioblastoma, an aggressive brain cancer. The treatment uses a patient's own immune cells, engineered to target a protein called EGFRvIII found on tumor cells, and modified to work better in the tumor's environment. 36 adults will receive a single infusion to check safety and see if tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metabolically Armed EGFRvIII CAR-T cells (Meta10-EGFRvIII)
What this could lead to: If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong: This is a very early, small safety trial (36 people). The therapy may not shrink tumors or could cause serious side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA (GBM)

Contacts and locations

Locations

The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.